Hello Everyone,
The stock (ARCT) appears to have been oversold within the last week few weeks of March. Considering an imminent rejection may take place. Be cautious of the value (either an immediate rejection) or a pull up towards (7.15-7.30) and then bearish momentum.
Not Investment Advice. For Educational and Analytical Purposes Only. (Be Aware and Stick To...
ARCT has been trading sideways for the better part of two months. In addition, it has recently exhibited a large spike in buy-back volume. This comes after a news report that states that Arcturus Therapeutics announced a “broad strategic collaboration to advance next generation of lipid-mediated mRNA therapeutics”. Moreover, the RSI has shown a drastic spike in...